58 results on '"Blom, Kim"'
Search Results
2. Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023
3. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
4. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
5. Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden
6. SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
7. Mucosal IgA protects against BQ.1 and BQ.1.1 infection
8. Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
9. High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022
10. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
11. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
12. Vaccine-induced correlate of protection against fatal COVID-19 in the old and frail during waves of neutralization resistant variants of concern
13. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial
14. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection
15. Rapid emergence of omicron sublineages expressing spike protein R346T
16. Psychosocial risk factors on hippocampal subfield volumes: the Medea‐7T study
17. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
18. Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022
19. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial
20. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
21. Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
22. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
23. Clonally heritable gene expression imparts a layer of diversity within cell types
24. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
25. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
26. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination
27. Neutralization of VOCs including Delta one year post COVID-19 or vaccine
28. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
29. Cortical cerebral microinfarcts on 7T MRI: Risk factors, neuroimaging correlates and cognitive functioning – The Medea-7T study
30. Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2
31. Divergent clonal differentiation trajectories establish CD8+ memory T cell heterogeneity during acute viral infections in humans
32. Hippocampal subfield volumes on 7T MRI in normal cognition, subjective memory impairment, and early Alzheimer’s disease
33. Cerebral microbleeds on 7 Tesla MRI in preclinical Alzheimer’s disease: The Medea‐7T study
34. Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
35. Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
36. Magnitude and Functional Profile of the Human CD4+ T Cell Response throughout Primary Immunization with Tick-Borne Encephalitis Virus Vaccine
37. Divergent Clonal Differentiation Trajectories Establish CD8 + Memory T Cell Heterogeneity During Acute Viral Infections in Humans
38. Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: the SMART-Medea study
39. Clonally distinct differentiation trajectories shape CD8+ memory T cell heterogeneity after acute viral infections in humans
40. Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R− Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity
41. Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden
42. Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-Infection
43. Breadth and Dynamics of HLA-A2– and HLA-B7–Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection
44. Automated Multi-Atlas Segmentation of Hippocampal and Extrahippocampal Subregions in Alzheimer’s Disease at 3T and 7T: What Atlas Composition Works Best?
45. NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection
46. The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education
47. Specificity and Dynamics of Effector and Memory CD8 T Cell Responses in Human Tick-Borne Encephalitis Virus Infection
48. The influence of vascular risk factors on cognitive decline in patients with Alzheimer's Disease
49. The influence of vascular risk factors on cognitive decline in patients with dementia: A systematic review
50. Differential Loss of Invariant Natural Killer T Cells and FoxP3+ Regulatory T Cells in HIV-1 Subtype A and Subtype D Infections
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.